Full-Time

Health Outcomes Liaison/Senior Health Outcomes Liaison

Field Medical Affairs

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Biotechnology
Healthcare

Compensation Overview

$170k - $205kAnnually

+ Annual Bonus + Equity

Senior

New York, NY, USA

Field based position in New York, NY.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • PhD, PharmD, MD, or DO) preferred. Candidates with a Master’s degree and significant relevant experience will also be considered
  • A minimum of 5 years of experience in a field based managed care, health outcomes role, or a hybrid HOL/payer role, or has a combination of industry & other payer related experience
  • Health outcomes, pharmaco-economics, population-based health management knowledge
Responsibilities
  • Communicate the clinical, economic, and humanistic value proposition of Axsome’s portfolio of products, in a fair and balanced manner, using approved resources, to healthcare population health decision makers including Pharmacy Directors, Medical Directors, Case Managers, Clinical Pharmacists, Formulary Decision Makers, etc. within payer organizations and to managed care professionals to ensure access to Axsome medications and improve patient outcomes
  • Collaborate closely with HEOR Strategy team, market access and other internal teams in development and execution of field-based tools
  • Compliantly coordinate activities with market access field team to ensure compliant and aligned account support
  • Identify opportunities to work with payers, academic institutions, and individuals to discuss research and facilitate initiation of HEOR research and evidence gap studies as aligned with strategy
  • Demonstrate leadership in area of evidence-based medicine and provide training and information to Field Medical and other functions as requested
  • Attend and provide support at relevant national and regional conferences throughout the year
  • Exchange information with population health decision makers and collect, synthesize and communicate actionable insights to internal stakeholders in order to help shape strategy and tactics
  • Be a Field therapeutic area expert demonstrating high scientific knowledge and competency in relevant therapeutic areas
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain to help regulate mood. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which helps speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Stage

IPO

Total Funding

$430.7M

Headquarters

New York City, New York

Founded

2012

Growth & Insights
Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Simplify Jobs

Simplify's Take

What believers are saying

  • The launch of Auvelity and the promising results of AXS-12 in Phase 3 trials indicate strong potential for revenue growth and market impact.
  • Axsome's strategic expansion of its sales force to support Auvelity's launch demonstrates its commitment to commercial success.
  • The appointment of experienced leaders like Dr. Sue Mahony to the board enhances Axsome's strategic direction and governance.

What critics are saying

  • The biopharmaceutical sector's inherent risks, including regulatory hurdles and clinical trial failures, could impact Axsome's progress.
  • High competition in the CNS disorder treatment market may challenge Axsome's ability to capture significant market share.

What makes Axsome Therapeutics Inc unique

  • Axsome Therapeutics focuses on CNS disorders with a strong emphasis on unmet medical needs, setting it apart from broader biopharmaceutical companies.
  • The FDA Breakthrough Therapy Designation for AXS-05 highlights its innovative approach and potential for rapid market entry.
  • Axsome's diversified pipeline, including treatments for MDD, TRD, Alzheimer's agitation, and narcolepsy, showcases its comprehensive strategy in CNS therapeutics.

Help us improve and share your feedback! Did you find this helpful?